<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04067531</url>
  </required_header>
  <id_info>
    <org_study_id>12</org_study_id>
    <nct_id>NCT04067531</nct_id>
  </id_info>
  <brief_title>Treatment of BV With First Deqularum and Then Direkt After Clindamycin</brief_title>
  <acronym>BV</acronym>
  <official_title>Treatment of BV With First Deqularum and Then Direkt After With Vaginal Clindamycin Cream.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skaraborg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Skaraborg Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of BV with first deqularum cloride and then followed with clindamycin vaginal
      Cream.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypoteses is that deqularum cloride takes away the biofilm so that clindamycin will kills
      the bacteria.

      Cure rate will be followed up after 1 month and then after 6 month
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cure of BV</measure>
    <time_frame>6 month</time_frame>
    <description>cure rate of BV</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Infection, Bacterial</condition>
  <arm_group>
    <arm_group_label>treatment of BV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>all patients be treated with first Deqularum then with clindamycin Cream,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treatment of BV with first Deqularum and then direkt after with vaginal clindamycin</intervention_name>
    <description>All patients will get the same treatment</description>
    <arm_group_label>treatment of BV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy women with BV

        Exclusion Criteria:

          -  women treated with antibiotics within 1 month
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>P-G Larsson</last_name>
    <role>Principal Investigator</role>
    <affiliation>professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>P-G Larsson</last_name>
    <phone>+46500431000</phone>
    <email>p-g.larsson@vgregion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Ob/Gyn, Skaraborgshospital Skövde</name>
      <address>
        <city>Skövde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per-Göran B Larsson, professor</last_name>
      <phone>+46500431000</phone>
      <email>p-g.larsson@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Karin Breding, dr</last_name>
      <phone>+46500431000</phone>
      <email>karin.breding@vgregion.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skaraborg Hospital</investigator_affiliation>
    <investigator_full_name>Per-Goran Larsson</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

